Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339271 | 0.93 | ALDH1A1 (0.58) | ALDH1A1HPGDKDM4EAHRLMNA | |
| Foslinanib SCHEMBL339075 | 0.91 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EAHRLMNA | |
| Foslinanib SCHEMBL31745350 | 0.91 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EAHRLMNA | |
| Foslinanib SCHEMBL339272 | 0.91 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EAHRLMNA | |
| Foslinanib SCHEMBL30738341 | 0.91 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EAHRLMNA | |
| Foslinanib SCHEMBL339074 | 0.90 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4EAHRLMNA | |
| SCHEMBL340201 | 0.89 | ALDH1A1 (0.65) | ALDH1A1HPGDKDM4EAHRLMNA | |
| SCHEMBL10199959 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HPGDKDM4EAHRLMNA | |
| SCHEMBL18040600 | 0.84 | HPGD (0.49) | ALDH1A1HPGDKDM4EAHRLMNA | |
| SCHEMBL10262955 | 0.84 | ALDH1A1 (0.49) | ALDH1A1HPGDKDM4EAHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | ALDH1A1 1258/4885HPGD 1841/4885KDM4E 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.